The race is on to find a vaccine for Covid-19, so when will one be ready? Video / AP
Testing of an experimental Covid-19 vaccine has begin in healthy volunteers in Britain, the latest in a cluster of early-stage studies in search of protection against the coronavirus.
University of Oxford researchers gave injections to volunteers in a study that eventually aims to include hundreds in the hope oftelling not only if the vaccine is safe but if it works.
Researchers created the new vaccine by inserting genes for a spiky protein that studs the outer surface of the new coronavirus into another, harmless virus.
The idea is the immune system will spot the foreign protein and make antibodies to fight it, primed to react quickly if the person eventually is exposed to Covid-19.
A person is being injected as part of the first human trials in the UK to test a potential coronavirus vaccine, untaken by Oxford University. Photo / AP
These kinds of studies often give volunteers either the real vaccine or a dummy shot. But this experimental vaccine may briefly cause soreness and maybe a low fever — meaning if a dummy shot was the comparison, the participants might figure out who got the real thing, said Dr Andrew Pollard, one of the Oxford chief researchers.
"That might influence people's behaviour, perhaps make them more likely to be exposed to the virus," which in turn would make it harder to prove if the vaccine worked, Pollard told The Associated Press.
So the Oxford team decided half the volunteers would be given an old vaccine against another disease that offered no Covid-19 protection but had similar shot side effects.
"It seems like the right thing to do — to ensure that we can combat this disease and get over it a lot faster," volunteer Edward O'Neill told the BBC afterward.
A person working inside the lab working on a potential Covid-19 coronavirus vaccine. Photo / AP
Dozens of vaccine candidates are in various stages of development around the world. Experts have cautioned that, even if early studies go well, it will be at least a year before any are available for widespread use.
Among those making the fastest progress is China's CanSino Biologics, which has begun the second phase of testing its vaccine candidate, made with an approach similar to Oxford's.
Two US companies are testing vaccines made from copies of a piece of the virus's genetic code. Two other Chinese candidates are being pursued that use older technology.
